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Gamma-aminobutyric acid (GABA) and glutamate are the primary neurotransmitters responsible for modulating
excitatory and inhibitory signalling within the human brain. Dysfunctional GABAergic and glutamatergic sig-
nalling has been identified as a key factor in a range of neuropsychiatric conditions; hence measurement and
modulation of these neurometabolites is important for improving our understanding of neuropsychiatric condi-
tions and treatment options. Gabapentin (GBP) is one of several drugs developed to increase GABA levels and is
routinely prescribed for conditions such as epilepsy and neuralgia. While animal and human studies indicate that
GBP can elevate GABA levels, its exact mechanisms of action are not fully understood, although animal studies
indicate that GBP does not have a direct effect upon GABAergic receptors.
To investigate the impact of acute GBP administration in the human motor system we used two complimentary
approaches – transcranial magnetic stimulation (TMS) and magnetic resonance spectroscopy (MRS). MRS and
TMS measures of GABA have repeatedly been found to be uncorrelated and are likely to reflect different pools of
synaptic and extra synaptic GABA, hence, measuring both within the same participants allows for an in-depth
assessment of GBP effects.
Despite significantly increased ratings of fatigue and tiredness within the GBP group, we failed to find any
statistically significant changes in our MRS or TMS measures of GABA. Measures of MRS Glutamate (glu) and
glutamine (gln) were also not affected by the administration of GBP. These findings are important as they run
counter to previous work, and suggest that the effect of an acute dose of GBP is likely to be subject to substantial
individual variation, with timing of measures particularly likely to impact observed effects. These findings have
implications for the use of acute GBP dosing as a means to explore GABAergic function in health and disease.1. Introduction
Gamma-aminobutyric acid (GABA) is the primary inhibitory neuro-
transmitter in the human brain. It is estimated to be present in 25–50% of
synapses and plays a critical role in maintaining neural excitability
within a functional range. GABA is synthesised from glutamate, which in
turn is derived from glutamine; all three form part of a metabolic cycle
which can be drawn upon for neurotransmission (Rae, 2014).k (K. Dyke).
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interventions.
Several drugs have been developed which have notable effects in
increasing GABA levels, one of which is Gabapentin (1-(aminomethyl)
cyclohexaneacetic acid [Neurontin®]) (GBP). GBP is a widely prescribed
drug, typically used to treat conditions such as epilepsy and neuralgia,
and was originally synthesised as an analogue of GABA. However, ex-
periments in animals found no evidence that GBP has a direct effect on
GABAergic receptors (Taylor et al., 1998 Ziemann et al., 2015). Thus,
GBP does not appear to interact directly with GABA-A or GABA-B re-
ceptors (Goa and Sorkin, 1993; Sills, 2006 Taylor et al., 1998), nor does it
appear to be a GABA-A (Kondo et al., 1991) or GABA-B agonist (Lanneau
et al., 2001). Instead, it is thought that GBP acts via α2δ
voltage-dependent calcium channel subunits (Ziemann et al., 2015), and
that its overall effect is to increase GABA synthesis and turnover (Loscher
et al., 1991). It should be noted that much of the research into the effects
of GBP has been conducted in rats, and it is significant that a study
comparing the effects of GBP in human and rat neocortical slices revealed
substantial differences (Errante et al., 2002). Caution is therefore war-
ranted when extrapolating from rodent to humans.
MRS and TMS are non-invasive approaches, which can be used to
measure concentrations and synaptic activity relating to several neuro-
metabolites including GABA and glutamate, within localised areas of
brain tissue. Consequently, these techniques have been applied to study
the underlying mechanisms of drugs such as GBP in the human brain.
Interestingly, while MRS and TMSmeasures of GABA appear to be largely
uncorrelated, and likely reflect different pools of GABA with distinctive
underlying mechanisms (Dyke et al., 2017; Stagg et al., 2011; Stagg et al.,
2011 Tremblay et al., 2013), both have been reported previously to be
modulated by GBP administration (Cai et al., 2012; Kuzniecky et al.,
2002; Petroff et al., 1996; Rizzo et al., 2001 Ziemann et al., 1996).
To our knowledge, two studies have explicitly used TMS to assess
changes in motor cortical excitability following acute administration of
GBP. These studies assessed the impact of GBP on various single and
paired pulse TMS measures, including short interval intra-cortical inhi-
bition (SICI), short interval intra-cortical facilitation (ICF) and motor
threshold (MT). SICI is a paired pulse TMS approach, during which a
subthreshold conditioning stimulus (CS) is delivered to the motor cortex
1–5 ms prior to a supra threshold test stimulus (TS) (Hanajima and
Ugawa, 2008). It is widely thought that the CS results in a short-lasting
inhibitory postsynaptic potential in corticospinal neurons via the acti-
vation of a low-threshold cortical inhibitory circuit. The engagement of
this circuit is then thought to inhibit the action potentials generated in
the same pool of corticospinal neurons in response to the subsequent TS
(see Ziemann (2013) for a review). When measured in the motor cortex,
the result of the CS-TS paring is a smaller motor evoked potential (MEP)
than that obtained from the TS alone. Animal models and pharmaco-
logical studies have suggested that the effects of SICI are strongly
mediated by the activity of GABA-A receptors (Hanajima and Ugawa,
2008 Ziemann, 2013); with a lesser contribution from GABA-B receptor
activity (McDonnell et al., 2006). Interestingly, while the general
consensus is that GBP does not directly impact GABA-A receptors (Goa
and Sorkin, 1993; Sills, 2006 Taylor et al., 1998); in humans 800 mg and
1200 mg doses of GBP have been reported to increase SICI 3 h after
administration (Rizzo et al., 2001 Ziemann et al., 1996). These findings
may suggest indirect mechanisms of action through which the overall
balance of excitation/inhibition is altered.
In contrast to SICI, ICF measures excitatory neuronal circuits within
the motor system. ICF is also measured using a paired pulse TMS
approach, however, the interval between pulses is set at 7–20 ms (Kujirai
et al., 1993), and although the facilitation of motor excitability is the
reverse of SICI effects, the underpinnings of these approaches appear to
be distinct (Ziemann, 2013). Mechanistically, both N-methyl-D-aspartate
(NMDA) receptor antagonists and benzodiazepines which positively
modulate GABA-A receptors have been found to reduce ICF (Ziemann,
2013). This suggests that ICF is in part modulated via processes that2
involve glutamatergic and GABAergic mechanisms. In both previous
studies, GBP was found to reduce ICF (Rizzo et al., 2001 Ziemann et al.,
1996).
Unlike SICI and ICF, MT has not been reported to be altered by GBP
(Rizzo et al., 2001 Ziemann et al., 1996). MT is measured using single
TMS pulses to identify the lowest stimulator output required to yield a
MEP approximately 50% of the time. MT is known to be effected by
voltage-gated sodium channel blockers such as carbamazepine (Menzler
et al., 2014 Ziemann et al., 1996) and is generally considered to reflect
cortico-cortical axons and their excitatory contacts with corticospinal
neurons (see Ziemann et al. (2015) for review). Hence, the lack of change
in this measure following GBP suggests that the drug does not cause
widespread change in motor cortical excitability through widespread
changes, which act on calcium and sodium channels. Rather, TMS studies
suggest that the effect of GBP is to modulate cortical excitability within
the motor cortex through indirect, non-synaptic, modulation of GABA
and (potentially) glutamate levels. However, neither of the TMS studies
reported here were placebo controlled, and there appears to have been no
subsequent attempts to establish the effects of GBP using TMS.
Evidence from MRS studies support the hypothesis that GBP in-
fluences GABA. Three notable studies have been documented, the first of
which was conducted by Petroff et al. (1996), in which elevated levels of
GABA in the occipital cortex were reported for patients with epilepsy
who were medicated with GBP compared with individuals who were
taking antiepileptic medications such as carbamazepine. These results
were dose specific, with those taking higher doses showing higher GABA
levels. In a more recent 7T MRS study conducted with healthy partici-
pants Cai et al. (2012), found that a single 900 mg dose of GBP signifi-
cantly elevated levels of GABA within the visual cortex. This elevation
was far greater than that seen in a control condition in which participants
were scanned twice within the same day, without drug or placebo
administration. Hence, the effects are unlikely to be accounted for by
natural GABA fluctuations over time. Finally, Kuzniecky et al. (2002)
studied the effects of acute and chronic doses of GBP in healthy partici-
pants using MRS at a field strength of 4.2 T. A single acute dose of the
drug (adjusted to participant’s weight (17 mg/kg)), caused significant
increases in GABA measures 6 but not 3 h after ingestion. Significantly
elevated levels of GABA were also measurable after a 4-week course of
the drug, although not after 2 weeks when compared to baseline levels.
Despite the common use of GBP, few double-blind, placebo-
controlled studies have been conducted in humans, and none have been
conducted using complimentary approaches within the same group of
subjects. This study aims to extend the existing literature using a double-
blind cross-over design, in which a range of TMS approaches, and MRS
measures acquired at ultra-high field (7T) were used to assess change in
cortical excitability and neuro-metabolites.
In addition to measurement of MT, SICI and ICF, we assessed changes
in input-output (IO curves) and long interval intra-cortical inhibition
(LICI), as the effects of GBP on these measures has yet to be studied. We
also make a distinction between 1 ms and 3 ms SICI, as the mechanisms
underlying the two appear to be different (Cengiz et al., 2013; Fisher
et al., 2002; Roshan et al., 2003 Vucic et al., 2009) and some (Stagg et al.,
2011), but not all (Dyke et al., 2017) have found a relationship between
1 ms but not 3 ms SICI and MRS GABA. IO curves are measured by
recording MEP amplitudes evoked from various intensities of TMS, they
allow the measurement of activity from neurons which are spatially
further away from the centre of activation and can be used as an index of
excitability within a wider region of the cortex. In particular, they are
thought to reflect the strength of corticospinal projections (Chen, 2000)
and are regulated by glutamatergic and GABAergic mechanisms in
addition to neurotransmitters including serotonin and noradrenaline
(Ziemann et al., 2015). Whereas LICI (Claus et al., 1992; Di Lazzaro et al.,
2002 Valls-Sole et al., 1992) is a paired pulse TMS approach thought to
be largely underpinned by the engagement of circuits linked to GABA-B
receptor activity (McDonnell et al., 2006).
In this study an ultra-high field (7T) scanner was used to acquireMRS.
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producing increased signal-to-noise ratio (SNR) and greater chemical
shift dispersion (Tkac et al., 2009). The increased SNR improves the
detection sensitivity and efficiency of metabolites, especially those with
low concentration such as GABA. Greater chemical shift dispersion in-
creases the separation of signals with similar resonant frequencies,
allowing a more accurate identification and quantification of each
metabolite. For instance, due to spectral overlapping the differentiation
of GABA, Glu and Gln signals are difficult in 1H spectra at field strengths
of 3 T or less (Puts and Edden, 2012), and Glx (a composite measure of
Glu þ Gln) is reported instead. By contrast, GABA, Glu and Gln become
separable at field strengths of 7 T or above.
2. Method
2.1. Participants
29 healthy, right-handed adults (age range 19–27) participated in the
study. All participants were free from neurological or psychiatric illness
and any contra-indications for MR scanning or TMS. Of the 29 partici-
pants tested, 14 were assigned to the placebo condition and 15 were
assigned to the GBP condition. During assignment efforts were made to
ensure that groups were approximately balanced for age, sex and BMI.
Due to the exclusion of one data set due to poor quality TMS in the
placebo group, and one data set from the GBP group due to poor quality
MRS data, there were slight variations between sample sizes. Participant
demographics for the different conditions can be seen in Table 1. All
participants completed MRI and TMS sessions before and after receiving
GBP/placebo (See Fig. 2).2.2. MR acquisition
MRI data were acquired using an ultra-high field 7T Philips Achieva
system (Philips Healthcare Best, Netherlands) with a 32-channel radio
frequency head coil at the Sir Peter Mansfield Imaging Centre (SPMIC),
University of Nottingham. Participants were placed supine and head-first
into the scanner. Foam pads were inserted between the participant’s head
and the coil to minimise and control head movement; a pair of prism
glasses was provided to allow participants to view a screen outside the
magnet bore.
At the start of each imaging session 1H image localiser and B0 maps
were acquired followed by BOLD-fMRI T2*-weighted images, which were
acquired to guide placement of the left primary motor cortex (M1)
spectroscopy voxel in the following MRS scans. The BOLD-fMRI used a
single shot EPI sequence (TR/TE¼ 1999/25 ms, FOV¼ 208 192 mm3,
matrix ¼ 112112, 30 slices, slice thickness ¼ 4 mm, no slice gap, 160
dynamics). During the fMRI scan, eight blocks of bimanual finger-to-
thumb opposition tapping were performed in a blocked-trial paradigm
as follows. The words ‘TAP’ and ‘REST’ were alternately displayed for 8s
and 32s, respectively. Participants were asked to tap their thumbs to each
finger with both hands simultaneously and continuously during the ‘TAP’
phase, and to rest (withhold movement) during the ‘REST’ phase.
Maximum activation of the left M1 was found by analysing the BOLD
response on-line using Philips IViewBOLD software.
T1-weighted anatomical images were then acquired with a MPRAGE
sequence (TR/TE/TI¼ 7.3/3.4/998 ms, FA¼ 8, FOV¼ 224224 120Table 1
Participant demographics for analysis of drug manipulation data. Data are pre-
sented as mean value  sd.
N Sex (m/f) Age BMI
Placebo MRS 14 8F, 6M 22.3  2.4 21.8  3.6
Placebo TMS 13 7F, 6M 23  2.5 22.1  3.7
Gabapentin TMS 15 7F, 8M 23.6  2.6 21.3  2.6
Gabapentin MRS 14 7F, 7M 23.6  2.4 21.9  2.6
3
mm3, isotropic resolution ¼ 1 mm3) for tissue segmentation. Anatomical
landmarks from these images were also used to assist in the placement of
the left M1 voxel for MRS.
In vivo 1H MRS data were acquired from a voxel of interest (VOI ¼
2020  20 mm3) placed over the hand area of the left M1 (Fig. 1A)
using a STEAM sequence (TE/TM/TR ¼ 17/17/2000 ms, sample size ¼
4096, spectral bandwidth ¼ 4000Hz, phase cycling ¼ 8, 288 averages,
9.6mins). Water suppression was performed using multiply optimised
insensitive suppression train (MOIST) (Murdoch, 1993). Prior to this, a
non-suppressed water reference spectrum (16 averages) from the same
VOI was acquired for eddy current correction and quantification. B0
shimming of the VOI was performed automatically by the Philips pencil
beam (PB) algorithm (Gruetter, 1993) in order to increase B0 field
homogeneity.2.3. TMS measurements and EMG recording
TMS was delivered using a Magstim Bistim system (Magstim,
Whiteland, Dyfed, UK) with a figure-of-eight magnetic coil (70 mm
diameter of each winding). The coil was held tangentially to the scalp and
positioned 45 from the midline, resulting in a posterior to anterior
current flow. Neuro-navigation software (Brainsight, Rogue Research
Inc., Montreal Quebec, Canada) was used in conjunction with individual
T1-weighted anatomical images to aid initial coil placement over the
hand area of left M1. Coil location was then refined using a hot spot
approach, in which the cortical location which consistently yielded the
largest motor evoked potential (MEP) amplitudes from the first dorsal
interosseous (FDI) muscle was identified as the optimal stimulation site.
Neuro-navigation was used throughout to ensure highly accurate coil
placement during and between the two TMS sessions.
MEPs were recorded using disposable Ag-AgCl surface electrodes
attached to the right FDI muscle in a belly-tendon montage. The signals
were amplified and bandpass filtered (10 Hz- 2 kHz, sampling rate 5 kHz)
then digitalized using Brainamp ExG (Brain Products GmbH, Gilching,
Germany) controlled by Brain Vision Recorder (Brain Products GmbH,
Gilching, Germany).
All trials were controlled using an in-house program (written using
Matlab: Mathworks, MA, USA), with an inter-trial interval (ITI) of 5s
occurring between each single/pair of pulses. Intra-cortical inhibition
and facilitation were investigated using a range of TMS paired pulse
protocols with various CS-TS pairings and ISIs of 1, 3, 10 and 12 ms
(Kujirai et al., 1993) and 100 ms (Claus et al., 1992 Valls-Sole et al.,
1992). IO curves were collected first with the order of intensities tested
full randomized. Immediately after paired pulse and unconditioned trials
were collected, also in a randomized fashion.2.4. Threshold determination
Resting motor threshold (RMT) was determined as the lowest in-
tensity needed to yield an MEP with a peak-to-peak amplitude of >50 μV
in the relaxed FDImuscle in aminimum of 5 of 10 trials. A 1mV (SI 1mV)
threshold was also determined by calculating the lowest intensity needed
to evoke an MEP of 1 mV in 5 of 10 consecutive trials.2.5. Input output curves
TMS intensities at 100, 110, 120, 130, 140 and 150% of RMT were
used. 10 pulses at each of the 6 intensities were delivered in a random-
ized order.2.6. Unconditioned trials
A total of 30 unconditioned trials were measured at SI 1 mV.
Fig. 1. [A] Position of the voxel of interest (VOI ¼ 2020  20mm3) located over the left-hand area of M1 shown in (i) sagittal, (ii) axial (iii) and coronal views. [B]
Standard deviations (shaded area) overlying the group mean in vivo spectrum acquired from the VOI obtained with STEAM sequence (TS/M ¼ 17/17 ms) at 7T are
shown (N ¼ 27). [C] A representative in vivo spectrum obtained from the M1 VOI is shown, together with its LCModel fit. Residual and fitted signals for metabolites of
interest and macromolecules (MM) and baseline (BL) are shown.
Fig. 2. Schematic showing study timeline. On average the second MRS measures were collected 2 h after drug/placebo intake. TMS measures were collected an
average of 3 h post intake.
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SICI was measured using 1 and 3 ms ISIs. The selection of condi-
tioning stimuli (CS) intensities was informed by previous work (Dyke
et al., 2018 Fisher et al., 2002) which revealed 1 ms SICI to have a lower
threshold than that of 3 ms SICI. CS intensities of 45,50,55 and 60% RMT
were used to measure 1 ms SICI, whereas 60, 65, 70 and 75% RMT were
used to measure 3 ms SICI. Each CS was followed by a supra-threshold
test stimulus (TS) of SI 1 mV delivered to the same location. Ten trials
were measured for each CS-TS pairing for both 1 and 3 ms ISIs.
2.8. Long interval intra-cortical inhibition (LICI)
A single ISI of 100 ms was tested using a supra-threshold CS of 110%
RMT and a TS delivered at SI 1 mV. A total of 20 trials were measured.
2.9. Intracortical facilitation (ICF)
10 and 12 ms ISIs were measured using a CS at 75% RMT followed by
a SI 1 mV TS 20 trials were measured for each ISI.
The testing sessions commenced at the same time eachmorning for all
participants and lasted approximately 6 h in total. Baseline MRImeasures
(T1 weighted anatomical and MRS) were collected first, approximately
30 min after this baseline TMS measures were collected, followed by a4
simple bespoke questionnaire to indicate their perceived level of fatigue
and tiredness on a scale of 1 (absent) to 10 (severe). Participants were
then given a drink containing 900 mg of GBP or with nothing added. A
strong sugar free blackcurrant flavoured drink was used to successfully
mask the taste of the drug. The researcher who administered the drink
and assigned participants to experimental conditions played no role in
the data analyses. All other researchers were kept blind to experimental
condition until processing of the data was completed.
After receiving the drug or control drink, participants ate a light lunch
which typically involved a sandwich, a low sugar snack such as crisps and
a low sugar drink (most typically water). During the break participants
were closely monitored and engaged in restful activities such as watching
films or reading. Participants were re-scanned on average approximately
2 h after consuming the control drink (117  18.5 min) or GBP con-
taining drink (122 12 min). The second set of TMS measurements were
then performed. On average these took place approximately 3 h
following control drink (167  16.5 min)or GBP intake (179  18.5). If
necessary, thresholds (RMT/SI 1 mV) were adjusted during the second
measurement. Finally, participants were asked to rate their level of fa-
tigue and tiredness again on the questionnaire. Participant comfort was
closely monitored throughout the experiment.
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The MRS data were processed using a MATLAB (The MathWorks Inc.,
Natick,MA, USA) routine developed in-house, prior to metabolite quan-
tification. Spectra from individual acquisitions and from all 32 receivers
were acquired from the scanner separately. These raw signals were
combined using the scheme reported by Hall et al. (2014), then phase
corrected and frequency aligned. In vivo 1H spectra were then fitted and
quantified with the LCModel software package (Provencher, 1993). The
basis set used for quantification included an experimentally acquired
macromolecule spectrum and model spectra for 20 metabolites. The
LCModel analysis was performed within the chemical shift range 0.2–4.2
ppm. Water scaling was applied using the non-suppressed water refer-
ence. The LCmodel control parameters were based on previously pub-
lished parameters (Tkac et al., 2009). Metabolites with Cramer-Rao
lower bound (CRLB) > 20% were rejected from further analysis. The
linewidth of in vivo spectra for the data collected at baseline was 10.35
1.99 Hz and 10.22  1.29 for data collected in the second session. Total
Cr (tCr, i.e., PCrþCr) was used as the internal reference for quantification
in accordance with previous recommendations (Danielsen and Ross,
1999; Stagg and Rothman, 2014) and MRS-GBP studies (Cai et al., 2012;
Kuzniecky et al., 2002 Petroff et al., 1996). The data were also analysed
without this correction (not shown but available upon request), and
revealed no additional statistical significant differences when assessing
change in metabolites following GBP or Placebo administration.
Tissue fractions within the MRS voxel were calculated using the T1
weighted anatomical data, segmented using SPM 12 (Ashburner and
Friston, 2005 Penny et al., 2006). Intraclass correlation coefficients (ICC)
and mean coefficients of variation (CV) calculated across individuals for
pre and post measures indicate good agreement between pre/post mea-
sures of grey matter (GM) (mean CV ¼ 16.3%, ICC(2,1)¼.78); white
matter (WM) (mean CV ¼ 7%, ICC(2,1)¼.81); cerebrospinal fluid (CSF)
(mean CV ¼ 18.8%; ICC(2,1)¼.81); and total tissue (mean CV ¼ 17.0%,
ICC(2,1)¼.81) within the MRS voxel. Although voxel placement was
similar, we applied the corrections below for tissue fraction to limit the
impact of subtle differences in voxel composition. All results were also
run without this correction, and revealed no additional statistically sig-
nificant differences.
(GABA concentration ratio / (GM%þWM%))*100
(Glu concentration ratio / (GM%þWM%))*100
(Gln concentration ration /(GM%þWM%))*100
2.11. Analysis of TMS data
All trials were carefully inspected visually and trials in which there
was evidence of pre-contraction of the FDI muscle within the period 500
ms prior to an MEPwere excluded. Themean amount of data excluded on
this basis for IO curves was below 2% for pre (1.73  3.32) and post
(0.096  2.22) measures. For paired pulse and unconditioned MEPs this
was less than 2.5% for pre (1.05  1.74) and post (2.25  4.29) mea-
sures. For the remaining data, peak-to-peak MEP amplitudes were
measured using in-house software (programmed using Matlab, The
Mathworks, MA, USA). When analysing individual participant data,
median values were calculated to indicate average MEP amplitude in
response to a particular stimulator output.
2.12. TMS recruitment (IO) curves
Single pulse TMS IO curves were measured by calculating for each
individual the median MEP amplitude for each given TMS intensity
(100–150% RMT). For two participants 150% was particularly uncom-
fortable, for these participants MEPs evoked from TMS intensities of5
100–140%RMT only were measured. The resultant median MEP values
for each intensity were fitted using linear slopes. R2 values for each time
point (pre/post) and group (GBP/Placebo) indicate good-excellent fits to
the data (mean  Sd of R2 values for pre placebo: 0.926  0.046; pre
GBP: 0.934  0.040; Post placebo: 0.919  0.062 and post GBP: 0.901 
0.959). For completeness, sigmoidal curves were also fitted to the data,
the results of which can be found in supplementary material. Fitting with
sigmoidal curves did not alter the conclusions in any material way.
2.13. Paired pulse data
Paired pulse trials were analysed by calculating for each individual
the median MEP amplitude for each CS intensity at each ISI. These values
were then divided by the median MEP amplitude for unconditioned trials
to create a ratio measure. For 1ms and 3ms SICI, numerous CS intensities
were measured. The ratios for each CS intensity assessed by calculating
the median of these ratios to indicate the average level of inhibition.
Further analysis of individual CS intensities for 1 and 3 ms SICI can be
found in Supplementary Material, including assessment of the data when
CS intensities were fitted with a linear slope. Baseline data showing
effective increase/decrease in MEP amplitudes as a result of the CS-TS
protocols for 1 ms SICI, 3 ms SICI and ICF can also be found in Supple-
mentary Material.
Although LICI was measured, we chose not to analyse the data
further. In the Placebo condition 7/13 data sets revealed total elimina-
tion of MEP during LICI at baseline, for participants in the GBP condition
this was apparent in 1/15. The abolishment of any MEP at baseline in so
many data sets makes pre/post comparisons problematic, particularly for
assessment of the placebo group as for many subjects an increase in LICI
is an impossibility.
2.14. Statistical analysis of TMS and MRS data
Statistical analysis were completed using JASP version 0.12.1.0
(JASP-Team, 2020) with the exception of intraclass correlation co-
efficients (ICC) calculations which were computed using SPSS version 25
(IBM-Corp, 2017). Assumptions for the use of parametric statistics were
assessed using relevant plots and statistical tests (QQ plot, Box-M, Sha-
piro-Wilk and Levene’s tests). Significant outliers were identified using
Grubbs test and removed prior to further analysis, these are detailed in
relevant sections. Effect sizes for parametric data are reported as partial
eta squared (η2p) for ANOVA and Cohens d (d) for t-test. For
Mann-Whitney U tests, effect sizes are reported as rank biserial correc-
tions (rrb), for Wilcoxon Ranked Sign, matched rank biserial correlation
values (rmrb) are shown.
Initial statistical analysis compared the two groups at baseline to
identify whether any systematic differences were present prior to the
administration of placebo/GBP. When relevant assumptions were met,
subsequent analysis using mixed models ANOVAs (within subjects factor:
time (pre/post); between subjects factor: group (placebo/GBP) were
conducted. For 12 ms ICF data, Wilcoxon ranked sign tests were used to
compare pre/post differences for each group as the assumptions required
for ANOVA were not met. Additional between-group comparisons were
conducted using change ratios (post/pre values) and independent sam-
ples t-tests/Man-Whitney U tests. Bayesian statistics are reported along-
side analyses of pre/post and ratio analyses. For mixed models ANOVAS
these were calculated in JASP with the order set to compare against data
modelled for the null hypothesis. Bayes factors are presented as BF01,
meaning values above 1 are suggestive of support for the null hypothesis
with larger values suggestive stronger support in favour of this over the
alternative. All Bayesian analyses were run with the alternative hy-
pothesis set as non-directional (akin to the two-tailed approach taken
with parametric measures).Cauchy prior values were kept at the default
value set in JASP of 0.707. For Bayesian Mann-Whitney U-tests the
number of samples was set at 1000.
Relationships between MRS and TMS measures were previously
K. Dyke et al. Neuroimage: Reports 1 (2021) 100003assessed and can be found in (Dyke et al., 2017).
3. Results: perceptions of tiredness and fatigue
Questionnaire data was obtained for 12/14 participants in the pla-
cebo groups and for 14/15 participants in the GBP group. There were no
statistically significant changes in ratings of fatigue (t(10) ¼ -0.77, p ¼
.459, d ¼ -.0232) or tiredness (t(10) ¼ -0.412, p ¼ .689, d ¼ -.124) in the
placebo group. In both instances Bayesian paired samples t-tests suggest
anecdotal (BF01 ¼ 2.617) and moderate (BF01 ¼ 3.124) evidence in
favour of the null. However, for the GBP group ratings of tiredness (t(13)
¼ -3.078, p ¼ .009, d ¼ -.823) and fatigue (Z¼-3.483, p¼.005, rmrb¼-1.0)
significantly increased. Bayesian paired samples t-tests for tiredness
(BF01 ¼ 0.083) suggest strong support in favour of the experimental
hypothesis. Relevant data are shown in Fig. 3.
4. Results: acute effects of GBP on TMS measures
4.1. Threshold values (RMT/SI1mv) and baseline differences
Independent samples t-tests were used to ensure that the TMS pa-
rameters used for IO curves and paired pulse measures were equivalent
between groups. These revealed no statistically significant differences
between RMT expressed as %Maximum stimulator output (MSO) for
placebo (M ¼ 46, SD ¼ 7.756) and GBP (M ¼ 45.866, SD ¼ 4.223) at
baseline (t(17.94)¼.055, p ¼ .955, d¼.022). Minor adjustments to RMT
in the post session occurred for 2 participants in the placebo group and 1
in the GBP group, no statistically significant differences between post
placebo/GBP measures were found (t(26) ¼ -0.163, p ¼ .872, d ¼ -.062).
Bayesian analyses revealed anecdotal support in favour of the null hy-
pothesis for differences between groups in pre (BF01 ¼ 2.823) and post
(BF01 ¼ 2.798) measures.
To ensure the MEP amplitudes did not differ between conditions, we
compared the median MEP amplitudes from the 10 pulses collected at
100%RMT during IO curvemeasurement. MannWhitney U tests revealed
no statistically significant differences between groups at baseline (U ¼
90, p¼ .747, rrb ¼ -.077) or post (U ¼ 119, p ¼ .339, rrb¼ .221). Bayesian
Mann-Whitney U-Tests revealed anecdotal support in favour of the null
hypothesis for differences between groups in pre (BF01 ¼ 2.607) and post
(BF01 ¼ 2.052) measures.
No statistically significant differences were found between SI1mV
values expressed as %MSO for placebo (M ¼ 54.846, SD ¼ 7.701) and
GBP (M ¼ 56.466, SD ¼ 6.446) at baseline (t(26) ¼ .-606, p ¼ .55, d ¼
-.230). As with RMT, minor adjustments were made to S1mV in the post
session. A total of four minor adjustments occurred for the placebo group
and three for the GBP group, no statistically significant differences were
found between the two groups post placebo/GBP (t(26) ¼ -0.892, p ¼
.381, d ¼ -.338). Bayesian analyses revealed anecdotal support in favour
of the null hypothesis for differences between groups in pre (BF01 ¼Fig. 3. Mean  SD self-report ratings of tiredness and fatigue shown A: pre (dark grey
GBP intake. Individual data points also shown in light grey.
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2.462) and post (BF01 ¼ 2.1) measures.
Assessment of the median amplitude of 30 pulses collected at S1mV
during paired pulse data collection using Man-Whitney U tests confirmed
that there were no statistical differences in MEP amplitudes produced by
SI1mV in the baseline condition (U¼ 130, p¼ .142, rrb¼ .333). However,
MEP amplitudes were significantly higher in the post placebo condition
(Mean ¼ 1609, SD ¼ 657) in comparison for the post GBP condition
(Mean ¼ 10991, SD ¼ 613.772), U ¼ 145, p ¼ .029, rrb¼ .487. Bayesian
Man-Whitney U tests suggest anecdotal support for the null hypothesis
for the existence of group differences at baseline (BF01 ¼ 1.505); and
anecdotal evidence in favour of rejecting the null (BF01 ¼ 0.638) when
exploring group differences in the post measures. Further inspection of
the data and analysis of ratio data (post/pre) detailed below, suggest this
is due largely driven by slightly higher MEPs overall in the post placebo
condition (see Fig. 4).
Independent samples t-tests confirmed that there were no baseline
differences between placebo and GBP groups for 1 ms SICI median in-
hibition (t(26)¼ -0.101, p¼ 920, d¼ -.038), 3 ms SICI median inhibition
(t(26) ¼ -1.348, p ¼ .189, d ¼ -.511) or 10 ms ICF (t(26)¼.226, p ¼ .823,
d¼.086). Mann-Whitney U tests also confirmed no statistically significant
differences between IO curve slope (U ¼ 107, p ¼ .683, rrb¼ .097) or 12
ms ICF (U ¼ 81, p ¼ .467, rrb ¼ -.169) at baseline. Equivalent tests run
using Bayesian approaches all provided anecdotal support in favour of
the null hypothesis and are as follows: 1 ms SICI (BF01 ¼ 2.815); 3 ms
SICI (BF01¼ 1.445); 10 ms ICF (BF01¼ 2.772); 12 ms ICF (BF01¼ 2.426);
Linear IO slope (BF01 ¼ 2.634).4.2. Impact of GBP/Placebo on TMS measures
Having established that no baseline differences exist between the two
groups, addition statistical analyses were conducted to explore any
change in measures across time points (pre/post) between groups (GBP/
placebo).4.3. SI1mV MEP amplitude
A mixed models ANOVA revealed no significant main effect of time
(f(1,26)¼.005, p¼ .942, η2p ¼ .000), or interaction (f(1,26)¼ 2.317, p ¼
.140, η2p ¼ .016) for MEP amplitudes. Bayesian repeated measures
ANOVA revealed moderate support in favour of the null for time (BF01 ¼
3.74) and the time* group interaction (BF01 ¼ 3.392).
Analysis of change ratios using an independent samples t-test
revealed no statistically significant differences between groups (t(26) ¼
1.710, p ¼ .099, d¼.648); however, Bayesian independent samples t-test
suggested very weak anecdotal evidence in favour of the experimental
hypothesis (BF01 ¼ 0.974). The placebo group showed a slight unex-
pected increase in MEP amplitude whereas the GBP group showed more
of a tendency towards decreased MEPS (see Fig. 4).) and post (light grey) placebo intake and B: pre (dark grey) and post (light grey)
Fig. 4. Mean  SD of MEP amplitudes obtained for SI1mV measures for pre (darker grey) and post (lighter grey) conditions in placebo and GBP groups. Individual
data points are shown in light grey.
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A mixed models ANOVA revealed no significant main effect of time
(f(1,26)¼.077, p ¼ .783, η2p ¼ .003), or interaction (f(1,26)¼.993, p ¼
.328, η2p ¼ .037) for IO curve slope. Bayesian repeated measures ANOVA
revealed moderate support in favour of the null for time (BF01 ¼ 3.426)
and substantial support for a null effect for the time* group interaction
(BF01 ¼ 9.577).
Comparison of the change ratio data between the two groups using a
Mann-Whitney U test also failed to reveal any statistically significant
differences (U ¼ 111, p ¼ .555, rrb¼.138). A Bayesian Mann-Whitney U
test revealed anecdotal support in favour of the null (BF01 ¼ 2.206).
Relevant data are shown in Fig. 5.4.5. SICI
Relevant data are shown in Fig. 6A and Fig. 6C. No significant main
effects of time (pre/post) (f(1,26)¼.047, p ¼ .829, η2p ¼ .002) or inter-
action between condition and time (f(1,26)¼.473,p ¼ .498, η2p ¼ .018)
were found for median inhibition measured using 1 ms SICI. Bayesian
repeated measures ANOVA revealed moderate support for time (BF01 ¼
3.761) and strong support for time* group interaction (BF01 ¼ 15.851) in
favour of the null hypothesis.
There were also no significant main effect of time (f(1,26)¼ 1.89, p¼Fig. 5. Mean  SD of MEP amplitudes for pre (black circles) and p
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.181, η2p¼ .068) or interaction (f(1,26)¼ 1.227, p¼ .278, η2p¼ .045) for
median inhibition as measured by the 3 ms SICI protocol. Bayesian
repeated measures ANOVA revealed anecdotal support for time (BF01 ¼
1.876) and moderate support for time* group interaction (BF01 ¼ 4.837)
in favour of the null. Additional statistical analysis performed using each
individual CS intensity also failed to reveal any statistically significant
results for either 1 or 3 ms SICI conditions (see Supplementary Material).
Mann-Whitney U tests revealed no statistically significant differences
between ratio of change in inhibition caused by 1 ms SICI protocols in the
placebo group vs GBP group (U¼75, p ¼ .316, rrb ¼ -.231). Nor were
there any statistically significant differences in change ratios were found
for inhibition caused by 3ms SICI (U¼ 125, p¼ .217, rrb¼.282). Bayesian
hypothesis testing revealed anecdotal support in favour of the null, for
differences between groups in 1 ms SICI (BF01 ¼ 1.745) and 3 ms SICI
(BF01 ¼ 1.804) ratio measures.4.6. ICF
Relevant data are shown in Fig. 6B and Fig. 6D. There was no sig-
nificant main effects of time (f(1,26)¼.224, p ¼ .640, η2p ¼ .009) or
interaction between condition and time (f(1,26)¼.116, p ¼ .736, η2p ¼
.004) for 10 ms ICF. Bayesian repeated measures ANOVA revealed
moderate support for time (BF01 ¼ 3.354) and strong support for the
time* group interaction (BF01 ¼ 21.175) in favour of the null hypothesis.ost (blue squares) conditions in placebo (A) or GBP (B) groups.
Fig. 6. Mean  SD values showing average inhibition/excitation calculated by dividing the median amplitude of MEP values for each CS by the amplitude of MEP
amplitudes obtained from unconditioned TS. A & B show before (dark grey) and after (light grey) placebo. C & D show before (dark grey) and after (light grey) GBP.
Dashed line indicates no change from unconditioned test pulses. Values above indicate facilitation, below indicate inhibition. Individual data are shown in light grey.
K. Dyke et al. Neuroimage: Reports 1 (2021) 100003Man-Whitney U tests also failed to reveal any statistically significant
difference between change ratios of 10 ms ICF for placebo and GBP
conditions (U¼ 95, p¼ .829, rrb¼.056), this analysis was performed with
one outlier removed from the ratio data in the placebo condition.
Bayesian Mann-Whitney U test using the same data showed anecdotal
evidence in favour of the null hypothesis (BF01¼2.760).
The assumption of equality of variance was violated for post mea-
sures, therefore, separate Wilcoxon Ranked sign tests were calculated in
place of ANOVA; these revealed no significant differences between pre
and post 12 ms ICF measured in in placebo condition (Z ¼ -.40, p ¼ .735,
rmrb ¼ -.121) nor in the GBP condition (Z ¼ 50 p ¼ .599, rmrb ¼ -.167).
Bayesian paired samples t-tests revealed moderate support in favour of
the null (BF01 ¼ 3.427) for the placebo group and anecdotal support in
favour of the null hypothesis for GBP (BF 01¼ 2.71).
An independent samples t-test for 12 ms ICF also revealed no statis-
tically significant differences between the two groups when assessing
change ratios (t(26)¼.5, p ¼ .621, d¼ .218). Bayesian independent
samples t-test using the same data suggests anecdotal evidence in favour
of the null hypothesis (BF01¼2.57).
5. Results: acute effects of GBP on MRS measures
5.1. Baseline
Independent samples t-tests revealed no statistically significant dif-
ferences between the two groups for baseline measures of Glu/tCR (t(26)
¼ 590, p ¼ 0.560, d ¼ -.223); Gln/tCR (t(26) ¼ -1.309, p ¼ 0.202, d ¼
-.495) or GABA/tCR (t(26) ¼ 0.214, p ¼ 0.832, d ¼ 0.081). Bayesian
independent samples t-test using the same data suggests anecdotal evi-
dence in favour of the null hypothesis for Glu/tCR (BF01 ¼ 2.484); Gln/
tCR(BF01 ¼ 1.503) and GABA/tCR(BF01 ¼ 2.783).
5.2. Impact of GBP/Placebo on MRS measures
5.2.1. Glu
A mixed models ANOVA found a significant effect of time (Pre/Post)
f(1,26) ¼ 9.067, p ¼ 0.006, η2p ¼ .259. But no significant interaction
between group and time f(1,26) ¼ 0.398, p ¼ .533, η2p ¼ .015 for Glu/
tCR measures. Bayesian repeated measures ANOVA revealed substantial
support for the alternative hypothesis regarding time (BF01 ¼ 0.1275)
and anecdotal support of the alternative hypothesis for the time* group
interaction (BF01 ¼ 0.59) ..
Follow-up paired samples t-tests revealed that this effect was largely
driven by a statistically significant decrease in Glu/tCR in the GBP group
(t(13) ¼ 2.716, p ¼ .018, d¼.726), but not in the placebo group (t(13) ¼
1.604, p¼ .133, d¼.429). Bayesian paired samples t-tests suggest there is
substantial evidence for a pre/post difference in the GBP group (BF01 ¼8
0.28) and anecdotal support for the null (BF01 ¼ 1.312) for placebo
group. However, considering the lack of significant interaction, this
should be treated with caution, particularly as this decrease is apparent in
both conditions (Fig. 7).
An Independent samples t-test revealed no statistically significant
differences between change ratios for Glu/tCR following GBP or Placebo
(t(26)¼.587, p ¼ .562, d¼.222). Bayesian independent samples t-test
using the same data suggests anecdotal evidence in favour of the null
hypothesis (BF01¼2.488).5.3. Gln
Grubs test revealed a significant outlier for one participant in the
placebo condition, this data point was consequently removed prior to
further analysis. A mixed model ANOVA found a significant effect of time
(Pre/Post) (f(1,25) ¼ 5.982, p ¼ .022, η2p ¼ .193) but no interaction
between time and groups (f(1,25)¼.154, p ¼ .698, η2p ¼ .005). Bayesian
repeated measures ANOVA revealed substantial support for the alterna-
tive hypothesis regarding time (BF01 ¼ 0.310) and anecdotal support of
the null hypothesis for the time* group interaction (BF01 ¼ 1.017).
Both groups showed a decrease in Glu in the second measurement
(Fig. 7). Post hoc paired samples t-tests revealed this to be non-significant
for the Placebo group (t(12) ¼ 1.883, p ¼ .084, d¼.522) and GBP group
(t(13) ¼ 1.733, p ¼ .107, d¼.463) when assessed individually. Bayesian
paired samples t-tests suggest there is anecdotal support for the alter-
native hypothesis (BF01 ¼ 0.918) for placebo, and anecdotal support for
the null in the GBP group (BF01 ¼ 1.123).
An Independent samples t-test revealed no statistically significant
differences between change in Gln following GBP or Placebo
(t(26)¼.628, p ¼ .535, d¼.237). Bayesian independent samples t-test
using the same data suggests anecdotal evidence in favour of the null
hypothesis (BF01¼2.441).5.4. GABA
A mixed models ANOVA found no statistically significant effect for
time (pre/post) (f(1,26)¼.599, p ¼ .446, η2p ¼ .023), and no significant
interaction (f(1,26)¼.000, p ¼ .986, η2p ¼ <.000). Bayesian repeated
measures ANOVA revealed anecdotal support for the null hypothesis
regarding time (BF01 ¼ 2.751) and strong evidence in support of the null
hypothesis for the time* group interaction (BF01 ¼ 23.591).
Assessment of ratio data using an independent samples t-test also
failed to show any statistically significant difference between GABA/tCR
change following GBP in comparison to placebo (t(26)¼.191, p ¼ .850,
d¼.072). Bayesian independent samples t-test using the same data sug-
gests anecdotal evidence in favour of the null hypothesis (BF01¼2.797).
Fig. 7. Mean  SD values showing CSF corrected measures of GABA, Glu and Gln as ratios to tCR. A: before (black) and after (grey) placebo. B: before (black) and after
(grey) GBP.
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Altered GABAergic function is a hallmark of many neurological and
psychiatric disorders. Therefore, the study of methods that can modulate
GABA through pharmacological means are of interest, as they may hold
therapeutic promise for several conditions. However, to maximize the
potential of these approaches it is important that mechanisms of action
are well explored and defined. In the current double-blind, placebo-
controlled study, we set out to investigate the effects of GBP on GABA-
mediated TMS measurements and MRS measures of targeted neuro-
metabolites (i.e., GABA, Glu, Gln). Specifically, we assess changes in
MRS measures of GABA, Glu and Gln, alongside TMS measures known to
be underpinned by GABAergic and glutamatergic mechanisms. While
previous studies have looked at the effects of GBP on MRS and TMS
separately, this study represents the first to do so in the same group of
participants within the same session. The main results of our study are
summarized below.6.1. Key findings
1 There was a significant effect of ingesting a single 900mg dose of GBP
on perceptions of fatigue and tiredness. Participants in the GBP group
reported statistically higher levels in comparison to the placebo
group.
2 However, the 900mg dose of GBP did not significantly alter any of the
TMS measures taken approximately 3 h after ingestion.
3 MRSmeasures taken approximately 2 h following GBP ingestion were
also not significantly altered when compared to the placebo group.
Specifically, there was no change in GABA.
4 Glu/tCR was significantly decreased following GBP administration,
but not placebo. While noteworthy, this should be treated with
caution as comparisons between groups failed to support a statisti-
cally significant effect.6.2. Effects of GBP on perceived tiredness and fatigue
Participants in the GBP condition reported statistically higher levels
of fatigue and tiredness in self-report questionnaires, which were taken
approximately 3.30–4 h following GBP uptake. Researchers who were
blind to experimental condition also noticed higher levels of fatigue in
these participants while coming out of the scanner (approximately 2.3 h
post ingestion) and during TMS. While tiredness and fatigue are well
documented side effects of GBP, the previous work exploring effects on
TMS/MRS measures did not systematically report this for each partici-
pant; although tiredness (Ziemann et al., 1996) and being mildly sleepy
(Cai et al., 2012) were listed as reported GBP side effects.
Interestingly, the relationship between tiredness/fatigue/wakeful-
ness and cortical excitability in healthy adults is rather unclear. Some
studies measuring SICI, have reported this to be reduced following9
prolonged periods of wakefulness (Kreuzer et al., 2011), however, others
have found increases (Manganotti et al., 2001) or no significant change in
the measure (Badawy et al., 2006 Manganotti et al., 2006). Increased
excitability within frontal regions from morning-evening and following
sleep deprivation has been reported using an EEG-TMS approach (Huber
et al., 2013); however, studies of morning-evening variation in the motor
cortex have typically failed to show any systematic change as a conse-
quence of time awake (Doeltgen and Ridding, 2010; Strutton et al., 2003;
ter Braack et al., 2019).
There is less available research assessing tiredness/fatigue/wakeful-
ness and MRS measured GABA; however, one study which examined
GABA change within the sensorimotor cortex over five time points from
early morning to early evening failed to find any significant systematic
change over time (Evans et al., 2010). This suggests that normal circadian
rhythms have limited impact on MRS-GABA levels.
Although we cannot fully equate our ratings of fatigue/tiredness to
the above studies of sleep deprivation/morning-evening change, we feel
that on balance it is unlikely that increased fatigue/tiredness masked any
real effects of the drug manipulation in our measures. Subsequent studies
with larger sample sizes may wish to systematically record and assess
this.6.3. Effects of GBP on TMS measures
GBP was not found to significantly alter any of the TMS measures
when compared with the placebo group. This was somewhat surprising,
as based on the previous literature (Rizzo et al., 2001 Ziemann et al.,
1996) it was expected that GBP would significantly increase SICI and
reduce ICF. To our knowledge, this study is the first to use a double blind,
placebo-controlled method to investigate the effects of GBP on TMS
measures. This study also appears to be the first not to show a clear effect
of GBP. It is not entirely clear why the present study failed to replicate
previous findings, although it is possible that subtle differences between
experimental designs may have contributed.
We employed a standardized dosing approach in which all partici-
pants in the GBP condition received a 900 mg dosage of the drug. We did
not tailor the dose to weight, however, post hoc calculation of this reveals
our dosage ranges from 10 to 18 mg per kg (mean ¼ 14.4, SD ¼ 2.7). We
cannot rule out that this dosage was too low, however it should be noted
that while the 900 mg dose used was lower than that use by Ziemann
et al. (1996) (1200 mg) it was nonetheless higher than the 800 mg used
by Rizzo et al. (2001). We explored the effect of weight/dose on subse-
quent change on TMS/MRS measures using correlational analysis, but
failed to find evidence of any significant relationships (data not shown
but available on request; largest correlation found between weight/dose
and change in 10 ms ICF (r(13)¼.372, p ¼ .173).
Another possible reason for the lack of replication may be the timing
between drug uptake and TMSmeasurement. On average the second TMS
measurements were taken 3 h after receiving GBP, this ranged from 2.36
K. Dyke et al. Neuroimage: Reports 1 (2021) 100003to 3.25 h between participants. In their study Rizzo et al. (2001) found
increased SICI and decreased ICF 3 h after participants received an 800
mg dose of GBP. This may suggest that in our study the duration between
measures was too short for some individuals. However Ziemann et al.
(1996), found significant effects of SICI and ICF after just 2 h. Unfortu-
nately, as different doses and timings were used in all studies it is not
possible to draw strong conclusions about the lack of effects seen here. If
a similar study were to be conducted it would be informative to measure
the effects over a prolonged period in order to map the time course of
GBP and its peak effects.6.4. Effects of GBP on MRS measures
Contrary to previous findings (Cai et al., 2012; Kuzniecky et al., 2002
Petroff et al., 1996), GBP did not significantly alter levels of MRS-GABA.
Nor did it have a significant impact on measures of Glu/tCR or Gln/tCR.
The only significant effect seen for the MRS analysis was a significant
reduction in Glu/tCR levels following GBP but not placebo. This should
be treated with caution, as the interaction between time and group was
not significant and comparison of change ratios (post/pre) for each group
failed to show statistical differences. Yet, subsequent correlational
analysis to assess any relationship between change in MRS measures and
GBP dose/weight revealed a significant association r(12)¼ .594, p ¼
.025), in which higher dose-weigh ratio was associated with higher levels
of Glu, this was not significant for GABA/tCR or Gln/tCR (analysis not
shown but available on request). One previous study reported measuring
Glu, and failed to find any change approximately 2.5 h after GBP
administration (Cai et al., 2012). Given the known interactions between
Glu and GABA, this finding is noteworthy and warrants further attention
if a similar study into GBP were conducted.
There are several methodological reasons whichmay explain why our
results differ to those reported previously. The first of which is the in-
terval between drug uptake and the second MRS scan. In our study,
approximately 2 h elapsed between drug intake and the second MRS scan
(range of 1.45–2.23 h). This is a little short of the 2.5 h interval reported
by Cai et al. (2012). Detailed information regarding GBP uptake and
impact on MRS-GABA is not readily available, however, it is of interest
that while Cai et al. (2012) found significantly elevated GABA levels 2.5 h
after drug uptake, similar effects were only found 6, but not 3 h after
intake by Kuzniecky et al. (2002), suggesting additional factors such as
dosage may also impact. An additional notable difference between our
MRS approach and that of the three previous studies (Cai et al., 2012;
Kuzniecky et al., 2002 Petroff et al., 1996), is that we placed our MRS
voxel over the primary motor opposed to occipital cortex. Although
GABA levels have been found to differ between regions (Greenhouse
et al., 2016), they have also been reported to be stable within subjects in
the motor cortex (Ferland et al., 2019 Yasen et al., 2017). It is not clear
why GBP would impact more on visual than motor regions, so while this
is notable for comparing methodologies it does not seem a likely expla-
nation for our lack of effects.
A further difference between this study and those previously con-
ducted, is that due to the length of this study participants were able to eat
immediately following drug consumption. Although this may seem
problematic, there is little evidence that gabapentin absorption is nega-
tively influenced by food. In fact, some studies have even found that
foods with higher levels of protein such as a milk based breakfast option
(Gidal et al., 1996) and chocolate pudding (Gidal et al., 1998) have been
found to moderately enhance absorption.
Finally, although our sample size is larger than past work exploring
effects of a single dose of GBP using TMS (N ¼ 6 (Ziemann et al., 1996);
N¼ 11 (Rizzo et al., 2001)) andMRS(N¼ 6 (Kuzniecky et al., 2002); N¼
11 (Cai et al., 2012), we acknowledge that it is still relatively small and in
some cases our analyses may be underpowered. Future studies should
carefully consider sample size with reference to previous work including
the data presented here.107. Summary
It is not clear why, despite evidence of altered physiological state
(fatigue/tiredness ratings) following GBP we observed no clear differ-
ences in either our TMS or MRS measures. It is possible that the MRS
measures were conducted a little too early to allow for enough change to
be measured, however TMS data were conducted at a similar interval
post drug ingestion to those in which significant effects were reported.
While our findings should not be taken as evidence that GBP does not
cause measurable GABA change, they do suggest that these effects may
be subject to substantial individual variation.Declaration of competing interest
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